Zobrazeno 1 - 10
of 238
pro vyhledávání: ''
Autor:
Ellis Tibbs, Xuefang Cao
Publikováno v:
Cancer Immunology, Immunotherapy. 71:2255-2266
This paper addresses the controversy of Granzyme B (GzmB) expression by murine Myeloid Derived Suppressor Cells (MDSCs). MDSCs are a heterogenous immature myeloid population that are generated in chronic inflammatory pathologies for the purpose to su
Autor:
Jenifer Widger, Anna Wasiuk, Tibor Keler, Li-Zhen He, Andrea Crocker, Henry C. Marsh, Laura Vitale, Jeff Weidlick, Crystal Sisson
Publikováno v:
Cancer Immunology, Immunotherapy
Cyclophosphamide plus fludarabine (C/F) are currently used to improve the expansion and effectiveness of adoptive cell therapy (ACT). However, these chemotherapeutics cause pan-leukopenia and adverse events, suggesting that safer and more effective c
Autor:
Peter Ellmark, Adnan Deronic, Mia Thagesson, Karin Enell Smith, Doreen Werchau, Anneli Nilsson
Publikováno v:
Cancer Immunology, Immunotherapy
Non-responders to checkpoint inhibitors generally have low tumor T cell infiltration and could benefit from immunotherapy that activates dendritic cells, with priming of tumor-reactive T cells as a result. Such therapies may be augmented by providing
Publikováno v:
Cancer Immunology, Immunotherapy
Immune checkpoint inhibitors against PD-1, PD-L1 and CTLA-4 have altered the treatment paradigm for various types of cancers in the past decade. However, they offer clinical benefits to only a subset of patients. Evaluation and identification of an a
Autor:
Xiu Liang, Jing Xiao, Jinfa Gu, Ai-Min Ni, Hai-Jun Hu, Hai-Lang Li, Lanying Sun, Jin-Qing Hu, Xinyuan Liu, Huai-Yuan Wang
Publikováno v:
Cancer Immunology, Immunotherapy
Although the recent treatment in melanoma through the use of anti-PD-1 immunotherapy is successful, the efficacy of this approach remains to be improved. Here, we explore the feasibility of combination strategy with the armed oncolytic adenovirus ZD5
Autor:
Kristina Witt, Susan Evans-Axelsson, Anders Bjartell, Andreas Lundqvist, Rebecka Hellsten, Martin Johansson
Publikováno v:
Cancer Immunology, Immunotherapy
There is an urgent need for new treatment options in metastatic drug-resistant prostate cancer. Combining immunotherapy with other targeted therapies may be an effective strategy for advanced prostate cancer. In the present study, we sought to invest
Autor:
Syunsuke Yasuda, Marino Nagata, Kensuke Oikawa, Akemi Kosaka, Celis Esteban, Yasuaki Harabuchi, Shohei Harabuchi, Hiroya Kobayashi, Takayuki Ohkuri, Mizuho Ohara, Takumi Kumai, Toshihiro Nagato, Jun Ueda, Hiroshi Funakoshi, Yuki Yajima, Ryusuke Hayashi, Kenzo Ohara
Publikováno v:
Cancer Immunology, Immunotherapy. 70:2301-2312
Stimulator of interferon genes (STING) contributes to anti-tumor immunity by activating antigen-presenting cells and inducing mobilization of tumor-specific T cells. A role for tumor-migrating neutrophils in the anti-tumor effect of STING-activating
Publikováno v:
Cancer Immunol Immunother
Triple negative breast cancer (TNBC) is a significant clinical problem to which immunotherapeutic strategies have been applied with limited success. Using the syngeneic E0771 TNBC mouse model, this work explores the potential for anti-tumor CD8(+) T
Publikováno v:
Cancer Immunol Immunother
Dendritic cells are potently activated by the synergistic action of CD40 stimulation in conjunction with signaling through toll like receptors, subsequently priming T cells. Cancer vaccines targeting the activation of dendritic cells in this manner s
Publikováno v:
Cancer Immunology, Immunotherapy
Background Immune checkpoint inhibitors induce robust and durable responses in advanced bladder cancer (BC), but only for a subset of patients. Xenovaccination has been proposed as an effective immunotherapeutic approach to induce anti-tumor immunity